 Home > Active Ingredient News > Drugs Articles > Eli Lilly's CDK4/6 inhibitor Verzenios gets MHRA approval for early breast cancer

Eli Lilly's CDK4/6 inhibitor Verzenios gets MHRA approval for early breast cancer

 Last Update: 2022-08-15
 Source: Internet
 Author: User

Tags

20 high schools

dna replication activity

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Eli Lilly's Verzenios (abemaciclib) has received marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the adjuvant treatment of Verzenios in combination with endocrine therapy for HR+, HER2-, high-risk node-positive early breast cancer (EBC) patien.

Breast cancer is one of the most common cancers in women worldwi.

The MHRA approval was based primarily on results from the Phase 3 monarchE trial, which met its primary endpoi.

As a CDK4/6 inhibitor, Verzenios selectively inhibits cyclin-dependent kinase 4/6 (CDK4/6), restoring cell cycle control and blocking tumor cell proliferati.

Last August, draft NICE guidelines recommended Eli Lilly's twice-daily oral Verzenios (abemaciclib) for the treatment of adults with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the bo.

In 2019, the total global breast cancer market reached US$22 billion, with drugs targeting HER2 or CDK4/6 dominated (68% of sales), and the breast cancer market is expected to grow by 9% annually from 2019 to 2029 , reaching $47 billi.

At present, a number of CDK4/6 inhibitors have been launched worldwide, in addition to Eli Lilly's Verzenio, Pfizer's Ibrance (palbociclib) and Novartis' Kisqali (ribocicli.

Reference source:

MHRA marketing authorisation granted for Eli Lilly's Verzenios as early breast cancer treatment

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Methyl-L-alanine3913-67-5

CAS No.: 3913-67-5

Industrial Grade

$1-1.04/KG FOB

High Purity 99% PEG MGF CAS 108174-48-7 Customized Peptides from China OUDA

CAS No.: 108174-48-7

Pharmacy Grade

$2-2.6/G FOB

Wholesales Purity 99 Peptides Powder Sema Tirz Retatrutide 5mg/10mg/15mg to Door From China

CAS No.: 2023788-19-2

Pharmacy Grade

$150-180/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.